- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | My body. My choice. Are we all talking about the same thing? | ||
| Mi | BeiGene announces positive phase 3 trial results for liver cancer treatment | ||
| Mi | Sanofi halts recruitment for trials assessing MS treatment | ||
| Mi | Merck and Cerevance to research novel targets in Alzheimer's disease | ||
| Mi | Michael J Fox Foundation awards Koneksa second research grant | ||
| Mi | FDA approves Bot Image's AI software for the detection and diagnosis of prostate cancer | ||
| Di | Strategic commitment | ||
| Di | Pfizer set to acquire Global Blood Therapeutics in deal worth $5.4bn | ||
| Di | AstraZeneca and Daiichi Sankyo get FDA approval for breast cancer drug | ||
| Di | NHS England launches hepatitis C screening scheme to reach 2030 elimination goal | ||
| Di | Bayer's Nubeqa receives FDA approval to treat metastatic prostate cancer | ||
| Di | Valneva and Pfizer initiate phase 3 Lyme disease vaccine study | ||
| Mo | Born strategic - Why great strategists are both born and made | ||
| Mo | AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn | ||
| Mo | ONS records a continued fall in UK COVID-19 infections | ||
| Mo | ICR research shows how skin cancer cells invade new tissues | ||
| Mo | bluebird bio reveals plans to launch two gene therapies | ||
| Mo | UK government's 'science superpower' ambitions to fail without clear plan, Lords committee warns | ||
| Fr | Amgen acquires ChemoCentryx in $3.7bn cash deal | ||
| Fr | Gilead Sciences set to acquire MiroBio in deal worth over $400m | ||
| Fr | NHS England to roll out continuous glucose monitors to all those with type 1 diabetes | ||
| Fr | Sanofi and Innovent Biologics to develop oncology drugs for patients in China | ||
| Fr | WHO launches funding appeal for greater Horn of Africa prompted by food crisis | ||
| 04.08. | The patient voice - the value of patient-reported outcomes in HTA | ||
| 04.08. | AstraZeneca and MSD's breast cancer drug Lynparza receives EC approval |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
